

Extended Data Table 1: Post-2021 Independent Benchmark Genes

63 genes from publications post-dating L2G training cutoff (2021) · Verified absent from all training sets



Tier1_Mendelian · 35 genes

ClinGen Definitive evidence · (Mendelian disease causative)

LDLR	APOB	APOE
BRCA1	TP53	CFTR
GCK	HNF1A	KCNJ11
MC4R	HBB	HBA1
DMD	PKD1	UMOD
APC	SNCA	LRRK2
GBA	MYBPC3	SERPINA1
F8	FMR1	HFE
LEP	LRP5	COL1A1
GJB2	SLC26A4	MYOC
ABCA4	HEXA	HLA-DRB1
TSHR	TG	

Tier1_Coding · 14 genes

Functional coding variants · (protein-altering mutations)

LPA CAD/Lp(a) levels	SLC30A8 T2D protection (LoF)
APOC3 Triglycerides/CAD	NOD2 Crohn's disease
PTPN22 RA/T1D R620W	TYK2 SLE/MS P1104A
APOL1 CKD G1/G2 variants	SLC2A9 Uric acid/gout
PNPLA3 NAFLD I148M	TM6SF2 NAFLD E167K
CFH AMD Y402H	TREM2 AD R47H
SORL1 AD trafficking	IRS1 T2D insulin resistance

Tier1_CRISPR · 7 genes

CRISPR/perturbation validated · (functional screen evidence)

PCSK9 LDL/CAD drug target	ANGPTL3 LDL/TG evinacumab	IRX3 Obesity FTO target
CHD8 Autism chromatin	WNT16 Bone density Wnt	MTNR1B Glucose/circadian


Tier1_Drug · 6 genes

FDA-approved targets · (2021-2024 approvals)

IL23R IBD anti-IL23	PPARG T2D thiazolidinediones	JAK2 MPN JAK inhibitors
CETP HDL/CAD inhibitors	CACNA1C Psych Ca channel	

Disease Categories · 17 areas covered

Comprehensive coverage across human disease



Source: data/processed/baselines/post2021_independent_benchmark_FINAL.tsv